Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

1331 publications found

  1. Owens M, Borges A, McGrath J, Stern MF. The Status of Medications for Opioid Use Disorder (MOUD) Provision in Washington State Jails, 2021. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2023
  2. Floyd AS, Silcox J, Cousin E, Irwin AN, Gray M, Bolivar D, Bratberg J, Arnold J, Al-jammali Z, Hansen RN, Hartung DM, Green TC. Readiness of community pharmacies to implement an opioid safety intervention. Journal of the American Pharmacists Association 2023:63(1):275-283.e1. [doi: 10.1016/j.japh.2022.10.031] PMID: 36496310 PMCID: PMC9870924
  3. Gray M, Shin SS, Silcox J, Flores D, Bolivar D, Irwin AN, Floyd AS, Bratberg J, Boggis JS, Hartung DM, Green TC. “Like it was just everyday business”: A qualitative study of pharmacy-based naloxone and syringe customer experience. Journal of the American Pharmacists Association 2023;63(3):838-846. [doi: 10.1016/j.japh.2023.01.013] PMID: 36872182 PMCID: PMC10198806
  4. Winstead T, Newman A, Maroon E, Banta-Green C. Unmet Needs, Complex Motivations, and Care for People Using Fentanyl in Washington State: A Qualitative Study. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2023
  5. Chaple MJ, Kunins HV, Nass MD, Benjamin AC, Viel CR, Bertone P, Marker L, Warren P, Hartzler B. Exploring the impact of external facilitation using evidence-based implementation strategies for increasing motivational interviewing capacity among outpatient substance use treatment providers. Journal of Behavioral Health Services & Research 2023;51:185-202. [doi: 10.1007/s11414-023-09871-2] PMID: 38030934
  6. Kingston S. Overview and Perspectives of Syringe Services Programs in Washington State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, February 2023
  7. Hartzler B. Is it time to broaden community dissemination of cognitive-behavioral therapy for substance use disorders: Charting pathways to ascend the remaining mountainside [commentary]. Clinical Psychology: Science and Practice 2023;30(2):147-149. [doi: 10.1037/cps0000138]
  8. Peavy KM, Adwell A, Owens MD, Banta-Green CJ. Perspectives on medication treatment for opioid use disorder in adolescents: Results from a provider learning series. Substance Use & Misuse 2023;58(1):160-162. [doi: 10.1080/10826084.2022.2136493] PMID: 36371698
  9. Banta-Green C, Duncan M. Treatment Medications for Fentanyl Use Disorder: Prescriber Practices and Support Needs in WA State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, September 2023
  10. Perez LG, Tucker JS, Pedersen ER, Troxel WM, Rodriguez A, Firth CL, Seelam R, Shih RA, D'Amico EJ. Neighborhood social environment change in late adolescence predicts substance use in emerging adulthood. Health & Place 2022;75:102807. [doi: 10.1016/j.healthplace.2022.102807] PMID: 35512503 PMCID: PMC10519144
  11. Dilley J, Firth C, Kilmer B. Cannabis legalization in Washington: Policy evolution and emerging evidence from the first nine years. IN: Pardal M (ed.). THE CANNABIS SOCIAL CLUB. Abingdon, UK: Routledge, 2023, pp. 155-186
  12. Green TL, Bratberg J, Irwin AN, Boggis J, Gray M, Leichtling G, Bolivar D, Floyd A, Al-Jammali Z, Arnold J, Hansen R, Hartung D. Study protocol for the Respond to Prevent Study: A multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Substance Abuse 2022;43(1):901-905. [doi: 10.1080/08897077.2021.2010162] PMID: 35213293 PMCID: PMC9720900
  13. Simpson TL, Kaysen DL, Fleming CB, Rhew IC, Jaffe AE, Desai S, Hien DA, Berliner L, Donovan D, Resick PA. Cognitive processing therapy or relapse prevention for comorbid posttraumatic stress disorder and alcohol use disorder: A randomized clinical trial. PLOS One 2022;17(11):e0276111. [doi: 10.1371/journal.pone.0276111] PMID: 36445895 PMCID: PMC9707793
  14. Bhatraju EP, Fuller C, Grekin P, Rockman S, Peavy KM. Mortality in an opioid treatment program. Journal of Psychoactive Drugs 2022;54(1):93-98. [doi:10.1080/02791072.2021.1909189] PMID: 33840354
  15. Lapham GT, Matson TE, Carrell DS, Bobb JF, Luce C, Oliver MM, Ghitza UE, Hsu C, Browne KC, Binswanger IA, Campbell CI, Saxon AJ, Vandrey R, Schauer GL, Pacula RL, Horberg MA, Bailey SR, McClure EA, Bradley KA. Comparison of medical cannabis use reported on a confidential survey vs. documented in the electronic health record among primary care patients. JAMA Network Open 2022;5(5):e2211677. [doi:10.1001/jamanetworkopen.2022.11677] PMID: 35604691 PMCID: PMC9127557
  16. O'Neal TJ, Bernstein MX, MacDougall DJ, Ferguson SM. A conditioned place preference for heroin is signaled by increased dopamine and direct pathway activity and decreased indirect pathway activity in the nucleus accumbens. Journal of Neuroscience 2022;42(10):2011-2024 [doi: 10.1523/JNEUROSCI.1451-21.2021] PMID: 35031576 PMCID: PMC8916759
  17. Doonan SM, Johnson JK, Firth C, Flores A, Joshi S. Racial equity in cannabis policy: Diversity in the Massachusetts adult-use industry at 18-months. Cannabis 2022;5(1):30-41 [doi: 10.26828/cannabis/2022.01.004] PMID: 37287662 PMCID: PMC10212236
  18. Firth C. Calls to Washington Poison Center for Intentional Exposure to Cannabis, 2017-2021. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, August 2022
  19. Kingston S, Newman A, Banta-Green C. Results from the 2021 WA State Syringe Service Program Health Survey. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, March 2022
  20. Nakata KG, Yin E, Sutlief E, Ferguson SM. Chemogenetic modulation reveals distinct roles of the subthalamic nucleus and its afferents in the regulation of locomotor sensitization to amphetamine in rats. Psychopharmacology 2022;239(2):353-364. [doi: 10.1007/s00213-021-05985-7] PMID: 34549316
  21. Singh S, Banta-Green C, Kingston S. Distribution of Safer Drug Smoking Supplies as a Public Health Strategy. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, January 2022
  22. Firth CL, Carlini B, Dilley J, Guttmanova K, Hajat A. Retail cannabis environment and adolescent use: The role of advertising and retailers near home and school. Health & Place 2022;75:102795. [doi: 10.1016/j.healthplace.2022.102795] PMID: 35344691 PMCID: PMC9189000
  23. Musyoka CM, Mbwayo A, Donovan DM, Mathai M. Student peer mentoring: Feasibility and acceptability of mHealth-based tool for alcohol and substance abuse prevention by peer mentors at a university in Kenya. PLOS Digital Health 2023;2(1):e0000177. [doi: 10.1371/journal.pdig.0000177] PMID: 36812633 PMCID: PMC9931292
  24. Hirchak KA, Lyons AJ, Herron JL, Kordas G, Shaw JL, Jansen K, Avey JP, McPherson SM, Donovan DM, Roll J, Buchwald D, Ries R, McDonell MG, HONOR Study Team. Contingency management for alcohol use disorder reduces cannabis use among American Indian and Alaska Native adults. Journal of Substance Abuse Treatment 2022;137:108693. [doi: 10.1016/j.jsat.2021.108693] PMID: 34952747 PMCID: PMC9086134
  25. Carlini BH, Garrett SB, Nims LN. The kids are not all right: E-cigarettes, cannabis co-use, and an emerging public health crisis: A commentary on Roberts et al. (2022). Journal of Studies on Alcohol and Drugs 2022;83(5):771-772. [doi: 10.15288/jsad.22-00167] PMID: 36136449
  26. Peavy KM, Banta-Green C. Methadone: An Old Medication with Untapped Potential. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, April 2022
  27. Kisicki A, Becker S, Chaple M, Gustafson DH, Hartzler BJ, Jacobson N, Murphy AA, Tapscott S, Molfenter T. Behavioral healthcare organizations’ experiences related to use of telehealth as a result of the COVID-19 pandemic: an exploratory study. BMC Health Services Research 2022;22:775. [doi: 10.1186/s12913-022-08114-y] PMID: 35698186 PMCID: PMC9189799
  28. Carlini BH, Garrett S, Firth C, Pinksy I. Cannabis industry marketing violations in Washington State, 2014-2019. Journal of Studies on Alcohol and Drugs 2022;83:18-26. [doi: 10.15288/jsad.2022.83.18] PMID: 35040756
  29. Merrill JE, Lopez G, Stevens AK, Singh S, Laws MB, Mastroleo N, Magille M, Monti P, Kahler CW. Discussion of alcohol consequences during a brief motivational intervention session: comparing those who do and do not increase readiness to change. Addiction Research & Theory 2022;30(4):279-287. [doi: 10.1080/16066359.2021.2021401] PMID: 37180491 PMCID: PMC10181841
  30. Peavy KM. How to ask if they’re getting addicted. Worried about someone’s drinking or drug use, but not sure what to say? There’s a counselling approach that can help. Psyche (website) 2022; April 8
  31. Hall K, Higgins F, Beach KF, Diriba K, Sladky M, McCall TC. Disruptions to U.S. local public health’s role in population-based substance use prevention and response during COVID-19. Substance Abuse Treatment, Prevention, and Policy 2022;17(1):73. [doi: 10.1186/s13011-022-00499-7] PMID: 36345019 PMCID: PMC9640804
  32. Kingston S, Banta-Green C. Care Navigation at Harm Reduction Programs: Community-Based “Meds First” Buprenorphine Program Preliminary Data. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2022
  33. Rosales R, Janssen T, Yermash J, Yap KR, Ball EL, Hartzler B, Garner BR, Becker SJ. Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19. Journal of Substance Abuse Treatment 2022;132:108648. [doi: 10.1016/j.jsat.2021.108648] PMID: 34742607 PMCID: PMC8566093
  34. Braciszewski JM, Idu AE, Yarborough BJH, Stumbo SP, Bobb JF, Bradley KA, Rossom RC, Murphy MT, Binswanger IA, Campbell CI, Glass JE, Matson TE, Lapham GT, Loree AM, Barbosa-Leiker C, Hatch MA, Tsui JI, Arnsten JH, Stotts A, Horigian V, Hutcheson R, Bart G, Saxon AJ, Thakral M, Grant DL, Pflugeisen CM, Usaga I, Madziwa LT, Silva A, Boudreau DM. Sex differences in comorbid mental and substance use disorders among primary care patients with opioid use disorder. Psychiatric Services 2022;73(12):1330-1337. [doi: 10.1176/appi.ps.202100665] PMID: 35707859 PMCID: PMC9722542
  35. Firth CL, Warren KM, Perez L, Kilmer B, Shih RA, Tucker JS, D'Amico EJ, Pedersen ER. Licensed and unlicensed cannabis outlets in Los Angeles County: The potential implications of location for social equity. Journal of Cannabis Research 2022;4:18. [doi: 10.1186/s42238-022-00120-5] PMID: 35410443 PMCID: PMC8996577
  36. Hatch MA, Wells EA, Masters T, Beadnell B, Harwick R, Wright L, Peavy M, Ricardo-Bulis E, Wiest K, Shriver C, Baer JS. A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients’ sexual risk behavior. Journal of Substance Abuse Treatment 2022;140:108826. [doi: 10.1016/j.jsat.2022.108826] PMID: 35751944
  37. Eakins D, Magarati M, Hess K, Egashira L, Singer S, Parker M. Tailoring Opioid Overdose Prevention for Diverse Groups within Tribal and Urban Indian Settings. A Toolkit for Providers and Community Organizations Serving American Indian/Alaska Native Communities. Seattle, WA: Seven Directions, University of Washington, March 2022, 75p.
  38. Owens MD, Ngo S, Grinnell S, Pearlman D, Bekemeier B, Cusworth Walker S. Co-producing evidence-informed criminal legal re-entry policy with the community: an application of policy codesign. Evidence & Policy 2022;18(2):356-375. [doi: 10.1332/174426421X16445109542161]
  39. Wadsworth E, Schauer GL, Hammond D. Home cannabis cultivation in the United States and differences by state-level policy, 2019-2020. American Journal of Drug and Alcohol Abuse 2022;48(6):701-711. [doi: 10.1080/00952990.2022.2132507] PMID: 36288408
  40. Eakins DR, Neilson EC, Stappenbeck CA, Nguyen HV, Davis KC, George WH. Alcohol intoxication and sexual risk intentions: Exploring cultural factors among heavy drinking women. Addictive Behaviors 2022;131:107314. [doi: 10.1016/j.addbeh.2022.107314] PMID: 35381432 PMCID: PMC9271756
  41. Schauer GL, Roehler DR, Hoots BE. Self-reported medical and nonmedical cannabis use: Results from the 2018 Behavioral Risk Factor Surveillance System in 14 states. Journal of Community Health 2022;47:641-649. [doi: 10.1007/s10900-021-01049-1] PMID: 35460471 PMCID: PMC9884044
  42. Banta-Green CJ, Owens MD, Williams JR, Sears JM, Floyd AS, Williams-Gilbert W, Kingston S. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State. Addiction Science & Clinical Practice 2022;17:34. [doi: 10.1186/s13722-022-00315-4] PMID: 35799210 PMCID: PMC9261214
  43. Moore KE, Siebert SL, Kromash R, Owens MD, Allen D. Negative attitudes about medications for opioid use disorder among criminal legal staff. Drug and Alcohol Dependence Rep 2022;3:100056. [doi: 10.1016/j.dadr.2022.100056] PMID: 36845981 PMCID: PMC9948914
  44. Dunbar MS, Seelam R, Tucker JS, Firth CL, Pedersen ER, Klein DJ, Rodriguez A, D'Amico EJ. Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults. Addictive Behaviors 2022;126:107185. [doi: 10.1016/j.addbeh.2021.107185] PMID: 34839070 PMCID: PMC8802812
  45. Rhee JU, Vieira VM, Firth CL, Pedersen ER, Dunbar MS, Timberlake DA. Concentration of cannabis and tobacco retailers in Los Angeles County, California: A spatial analysis of potential effects on youth and ethnic minorities. Journal of Studies on Alcohol and Drugs 2022; 83(4): 502-511. [doi: 10.15288/jsad.2022.83.502] PMID: 35838427 PMCID: PMC9318698
  46. Banta-Green C, Williams J. Overdose Deaths Involving Pharmaceutical Opioids in Washington State from 2010-2021. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, November 2022
  47. Lee CM, Calhoun BH, Abdallah DA, Blayney JA, Schultz NR, Brunner M, Patrick ME. Simultaneous alcohol and marijuana use among young adults: A scoping review of prevalence, patterns, psychosocial correlates, and consequences. Alcohol Research: Current Reviews 2022;41(1). PMID: 35548267 PMCID: PMC9059839
  48. Carlini BH, Schauer GL. Cannabis-only use in the USA: Prevalence, demographics, use patterns, and health indicators. Journal of Cannabis Research 2022;4:39. [doi: 10.1186/s42238-022-00143-y] PMID: 35864553 PMCID: PMC9306107
  49. Coles CD, Grant TM, Kable JA, Stoner SA, Perez A, Collaborative Initiative on Fetal Alcohol Spectrum Disorders. Prenatal alcohol exposure and mental health at midlife: A preliminary report on two longitudinal cohorts. Alcohol: Clinical & Experimental Research 2022;46(2):232-242. [doi: 10.1111/acer.14761] PMID: 35157325 PMCID: PMC8867925
  50. Peavy KM, Banta-Green C, Owens M. Helping People Who Use Opioids and Stimulants. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, April 2021